A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.
Eligibility criteria
Qualifiers
Participants with confirmed squamous or non-squamous NSCLC with a current Stage IV mNSCLC.
Provision of acceptable archival tumour tissue (or fresh tumour tissue biopsy if archival tumour tissue is not available and if clinically feasible) is mandatory at screening.
Measurable disease as defined by at least one lesion that can be accurately measured at baseline as ≥ 10 mm at the longest diameter.
Minimum life expectancy of 12 weeks in the opinion of the investigator.
Disqualifiers
Participants with epidermal growth factor receptor mutations, anaplastic lymphoma receptor fusions or any other known genomic alteration for which targeted therapy is approved in the first line per local standard of care.
Presence of small cell and neuroendocrine histology components.
Any severe or uncontrolled systemic diseases, including uncontrolled hypertension, and active bleeding diseases, ongoing or active known infection; interstitial lung disease/pneumonitis (of any grade); unstable and/or symptomatic venous thromboembolism, serious chronic gastrointestinal conditions associated with diarrhoea, active non-infectious skin disease or substance abuse.
Has had a prior stem cell, bone marrow, allogenic tissue, or solid organ transplant.
Trial design
Treatments tested in this trial
- Rilvegostomig
- Cisplatin
- Carboplatin
- Pemetrexed
- Paclitaxel
- Nab-paclitaxel
- Ramucirumab
Treatment groups
152 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov